1-3 of 3
B. Douglas Smith, M.D.
Close
Sort by
Journal Articles

Treatment Persistence with Azacitdine (Vidaza) Is Associated with Lower Inpatient Hospitalization Costs Over Time

B. Douglas Smith, M.D., Dalia Mahmoud, MBA, Stacey Dacosta Byfield, Henry J Henk, PhD
Journal: Blood
Blood (2012) 120 (21): 4231.
https://doi.org/10.1182/blood.V120.21.4231.4231
Published: 2012
Journal Articles

Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders

Michael A McDevitt, MD, PhD, Brian D Koh, Anand Patel, Alison R. Moliterno, MD, Weijie Poh, James G. Herman, MD, Robert L Dilley, B. Douglas Smith, M.D., Judith E. Karp, MD, Jaroslaw P Maciejewski, MD, PhD, Scott H. Kaufmann, MD, PhD, Keith W. Pratz, MD
Journal: Blood
Blood (2011) 118 (21): 400.
https://doi.org/10.1182/blood.V118.21.400.400
Published: 2011
Journal Articles

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

Ian W Flinn, M.D., Ph.D., John C. Byrd, M.D., Richard R Furman, MD, Jennifer R Brown, MD, PhD, Don M Benson, MD, PhD, Steven E Coutre, MD, Brad S Kahl, M.D., B. Douglas Smith, M.D., Nina D. Wagner-Johnston, MD, Stephen E Spurgeon, MD, Neill A. Giese, Ph.D., Albert S Yu, MD
Journal: Blood
Blood (2009) 114 (22): 922.
https://doi.org/10.1182/blood.V114.22.922.922
Published: 2009